

For Immediate Release:

August 20, 2009

Contact:

Mary Kuramoto

513-579-9911 x 2523

m.kuramoto@medpace.com**Medpace announces the addition of Patricia E. Cole, PhD, MD, Executive Director Imagepace, strengthening Medpace services in clinical imaging**

CINCINNATI, OH (August 20, 2009) — Medpace, Inc. today announced the addition of Patricia E. Cole, PhD, MD, as Executive Director Imagepace. As head of Imagepace, Dr. Cole will advance Medpace's position as an industry leader in designing and executing clinical trials utilizing the most advanced imaging and biomarker technologies.

"The addition of Dr. Cole strengthens our clinical imaging business and will help Sponsors utilize advanced imaging technologies in clinical trial programs," said August Troendle, CEO and President, Medpace. "Imagepace will continue to provide our Sponsors with a consistent, end-to-end suite of image acquisition, collection and analysis services as well as to champion the use of imaging to enhance and expedite drug development."

Dr. Cole comes to Medpace with a wealth of experience in clinical medical imaging, biomarker development, experimental clinical development, radiology and medical devices in both international pharmaceutical and university environments. She has received numerous research grants as well as national fellowships and awards. Dr. Cole has served extensively on university, state, and national committees and is a contributing member of multiple national and international professional societies. In addition, she has published many papers and reviews, and delivered numerous national and international presentations.

Dr. Cole obtained her MD from The Albert Einstein College of Medicine and completed her diagnostic radiology residency and a cardiovascular / interventional fellowship at The New York Hospital – Cornell Medical Center. Prior to entering the radiology field, she obtained her PhD in biophysical chemistry from Yale University and completed a molecular biology postdoctoral fellowship at the Institute of Cancer Research, Columbia University College of Physicians and Surgeons. Dr. Cole's radiology faculty positions include Memorial Sloan Kettering Cancer Center and Yale University as well as faculty positions in chemistry at Columbia University and molecular biophysics and biochemistry at Yale University.

Before joining Medpace, Dr. Cole was Senior Director and Global Head of Imaging Biomarkers at Eisai Global Clinical Development. Prior to that she was a Director at Novartis Pharmaceuticals Corporation in Experimental Development and then a Director in their Clinical Imaging Unit in Biomarker Development. "Dr. Cole has extensive experience in clinical medical imaging across therapeutic areas, and will be a key leader in the continued growth of Imagepace in the clinical trial imaging market," said Catherine Soldano, Medpace Executive Director, Business Development.

Imagepace, one of the Medpace family of businesses, is a medical imaging core laboratory with clinical trial experience in the disciplined management of standard and innovative imaging modalities.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. In June 2009 Medpace was rated as the best CRO by U.S. Investigators in the 2009, CenterWatch Site Survey.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 1,000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and centralized imaging core laboratory management and reading from Imagepace.

Visit the Medpace website at www.medpace.com